As biopharma anticipates the “Facility of the Future,” a definition of what closed processing is, and quantification of its value, can be helpful information.
Sarah Le Merdy
Advertisement
Sarah Le Merdy is Systems and Single-Use Global Strategy Deployment Manager at Life Science business of Merck KgaA, Darmstadt, Germany.
Articles by Sarah Le Merdy
The combination of modular facilities and closed processing offers significant advantages in the production of biopharmaceuticals and is becoming a compelling option for manufacturing.
Advertisement
Latest Updated Articles
Perceptions and Considerations for Adopting Closed ProcessingPublished: March 30th 2023 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
5
